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ABSTRACT
Objective: Drug resistance is an imperative issue in the treatment of patients with lung cancer. In this work, investigation of the drug resistance 
mechanism of G2032R mutation in ROS1 is carried out using computational simulation techniques.
Methods: Molecular docking and molecular dynamics (MD) simulation approach have been utilized to uncover the mechanism behind crizotinib 
resistance in ROS1 at a molecular level. Normal mode analysis was carried out using ElNemo server which examines the movements and conformational 
changes in the protein structure. ArgusLab, PEARLS, and Autodock were employed for the docking analysis, whereas GROMACS package 4.5.3 was 
used for MD simulation approach.
Results: The results from our analysis indicates that wild-type ROS1 (Protein Data Bank Code 3ZBF) could be more crucial for the crizotinib binding 
as it indicates largest binding affinity, minimum number of H-bonds, and higher flexibility than mutant-type ROS1. Moreover, the theoretical basis for 
the cause of drug insensitivity is the differences in the electrostatic properties of binding site residues between the wild and mutant ROS1 structures. 
Our analysis theoretically suggests that E-2027 is a key residue responsible for the ROS1 drug selectivity.
Conclusion: Molecular docking and MD simulation results provide an explanation of the resistance caused by G2032R and may give a key clue for the 
drug design to encounter drug resistance.
Keywords: ROS1, Crizotinib resistance, Molecular docking, Normal mode analysis, Molecular dynamic simulation.
INTRODUCTION
Lung cancer is a malignant form of tumor which is seen in the lung 
tissues. Most of the tumors are imitative from epithelial cells. The 
information has proven that among all the cancers, lung cancer 
ranks second in the occurrence and first in mortality [1]. Since the 
introduction of ROS1 inhibitors, most particularly, crizotinib has 
significantly improved survival of the patients. However, prolonged 
therapy for >3 years invariably results in crizotinib resistance [2,3]. 
About 50% of the resistance arises from the second site mutations 
such as L1196M, C1156Y, F1174L, and G1269A in anaplastic lymphoma 
kinase (ALK) and G2032R in ROS1. These mutations consequences in 
decreased affinity to crizotinib thus result in a poor drug efficacy. ROS1 
is an oncogene belongs to the tyrosine kinase receptor family. It was first 
discovered in sarcoma RNA tumor virus. Rearrangement in the ROS1 
gene leads to fusion of a portion of ROS1 that incorporates the tyrosine 
kinase domain and the proceeding fusion kinase will lead to changes 
in the cell [4]. ROS1 rearrangements occur in various types of cancers 
such as non-small cell lung cancer (NSCLC), cholangiocarcinoma, gastric 
cancer, ovarian cancer, and glioblastoma. Crizotinib resistance is placed 
on chromosome 6 at position 23 of Homo sapiens, and usually, 2% of 
NSCLC cases are due to ROS1 mutations [5,6]. Awad et al. revealed a 
secondary mutation by performing a biopsy of lung tumor and found 
that glycine to arginine substitution at codon 2032, i.e., G2032R 
mutation in the ROS1 kinase domain. Generally, the metastatic process in 
lung cancer cells makes surgery and radiation complicated to function, 
and in that case, only chemotherapy is the only option for treatment. 
Targeted drug therapy is cytostatic (kills only the tumor cells) while 
the chemotherapeutic agents kill cells apart from cancer cells [7,8]. 
The 5-year endurance rate for NSCLC is <15%. Crizotinib take actions 
against ROS1 the with mechanism of adenosine 5’-triphosphate (ATP) 
competitive kinase inhibitor, anticipating binding of ATP and ensuing 
autophosphorylation, which is needed for launching of the enzyme [9]. 
In spite of the fact that crizotinib has substantiated itself as a productive 
counter to ROS1-type NSCLC, obtained resistance has made its 
advantageous impacts impermanent and has risen as a noteworthy 
barricade for crizotinib [10]. Despite the available reports on resistance 
by G2032R mutation in ROS1, the critical role of binding site residues 
flexibility and differences in the electrostatic properties of binding site 
residues are less well defined [11]. However, how mutation G2032R in 
ROS1 really presents drug resistance is not surely known. Resistance to 
crizotinib is a noteworthy general well-being issue as few medications 
exist to battle this ailment. Along these lines, resistance against even 
one of the accessible medications is a noteworthy general public health 
issue. Resistance mechanism of kinase inhibitors has been studied with 
the help of MD simulation [12]. These circumstances recommend the 
improvement of novel and more thriving ROS1 inhibitors, particularly 
for the management of drug resistance NSCLC. Hence, a normal mode 
analysis (NMA), molecular docking, and molecular dynamics (MD) have 
been carried out for the wild- and mutant-type ROS1 so as to provide 
the detailed information on the primary source of crizotinib resistance 
in NSCLC due to the G2032R mutation.
METHODS
Data set
The three-dimensional (3D) structure of wild ROS1 structure (Protein 
Data Bank [PDB] Code: 3ZBF) was recovered from the crystal structures 
of the PDB (Brookhaven PDB) for the investigation [13]. The mutant 
(G2032R) structure was generated using Swiss PDB Viewer [14]. The 
molecules of the drug were gathered from PubChem, a database kept up 
in the NCBI [15]. With the assistance of SMILES strings, the 3D structure 
© 2017 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
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of molecules was developed utilizing CORINA server. All the heteroatom 
and water molecules were removed before performing MD simulations.
Identification of binding site residues of ROS1
The ROS1 structure binding site residues were inspected utilizing 
ligand contact tool (LCT) program [16]. It produces representation two-
dimensional representations of protein-ligand complex structures from 
the usual PDB information. The LCT tool distinguishes the binding site 
residues in their respective structures based on distance calculation. 
The binding site residues are regarded as in association while one of 
its molecules is in 0.5 Å + van der Waals radii cutoff. In the present 
investigation, a complex of mutant structure with crizotinib was 
submitted into this tool to distinguish the residues of the binding site 
in the objective proteins.
Flexibility of binding site residues by NMA
The significant calculation of the atomic movements of residues of 
binding can be acquired from the mean square fluctuations of the atoms 
against their regular positions. These estimations can be identified 
with the B-factor. B-factor investigation gives comprehension of 
stability, dynamics, and flexibility of amino acids [17]. Protein flexibility 
assumes a critical part in protein flexibility and designing of the drug 
molecules [18]. There are different sorts of contacts which require 
flexibility of certain amino acids. For the comprehension of binding 
efficiency, amino acid flexibility in drug binding pouch is thought to 
be a noteworthy parameter. The flexibility loss ruins the binding effect 
and the other way around [19]. In this manner, we have examined the 
flexibility of the amino acids, mean square displacement (R2) by the 
ElNemo program [20].
Computation of docking energy
In the present study, different docking calculations were utilized to 
compute the binding productivity of ligand with target protein. It is 
trusted that various docking approaches positively supportive for the 
removal of errors in the docking computation [21,22]. In particular, 
ArgusLab docking algorithm and PEARLS algorithm were employed 
in our analysis for the prediction of crizotinib binding efficiency. 
The ArgusLab 4.0.1 docking program had been widely approved 
with docking precision at ~3 Å for root mean square deviation 
(RMSD) esteem between the anticipated and unique crystallographic 
posture [23]. The flexible ligand docking of ArgusLab was accessible by 
depicting the ligand as a torsion tree. Gatherings of reinforced atoms 
that did not have rotatable bonds were nodes, while torsion was the 
associations between the nodes. Topology of a torsion tree was an 
important element impacting proficient docking. For the docking 
estimations, the scoring strategy AScore (empirical scoring function) 
was being utilized. AScore depended upon on the total protein-ligand 
binding efficiency, considering the accompanying commitments: 
The van der Waals collaboration between the ligand and the protein, 
the hydrophobic impact, the hydrogen bonds between the ligand and the 
protein, the impact of deformation, and the impacts of the translational 
and rotational entropy loss in the binding procedure, individually [24]. 
The AScore function with the parameters read from the AScore.prm 
record was utilized to ascertain of binding energies of the subsequent 
docked structures. The record contained the coefficients for every term 
in the scoring function.
PEARLS software is used for computing small molecule ligand-protein, 
ligand-nucleic acid, protein-nucleic acid, and ligand-protein-nucleic 
acid interaction energies. The PEARLS services were available at 
http://ang.cz3.nus.edu.sg/cgi-bin/prog/rune.pl. The binding affinity 
of the wild-type ROS1 complex and mutant-type ROS1 complex was 
obtained from PEARLS [25]. Finally, Auto Dock 4.2, which was regarded 
as the greatest docking technique to find the free binding free energy 
(ΔG), utilized in our examination. In this docking tool, we utilized 
semi-flexible docking methods as a part, of which the objective protein 
was kept inflexible all through the docking and the ligand was kept 
flexible to investigate self-assertive number of torsional degrees of 
freedom additionally the six spatial degrees of flexibility crossed by the 
translational and rotational constraints. AutoDock utilizes Lamarckian 
genetic algorithm to explore the best conformers. The grid separating 
was set to 0.375 Å, and for every molecule, a most extreme of 10 docking 
runs were executed. The active site was defined using AutoGrid utility 
with 126 × 126 × 126 points to cover the entire region occupying the 
active site residues of ROS1 [26].
MD simulation
GROMACS is an amazingly fast tool for figuring the non-bonded 
contacts. It is handed out free of charge covered by the GNU Public 
license (http://www.gnu.org/). GROMACS version 4.5.3 was utilized 
to perform simulations of the wild and mutant types of ALK and ROS1 
structures [27]. With the assistance of periodic limit conditions and 
the SPC water display, the protein was solvated in cubic 0.9 nm [28]. 
PRODRG server was utilized to produce topology of the ligand. This 
server utilizes the GROMOS force field for creating topology record 
and allowing the types of atom. One thousand steps of steepest descent 
energy minimization were completed for the proteins. System was 
equilibrated at steady temperature and pressure. Utilizing an atom-
based close off of 8 Å, the non-bonded account was created. The long-
range electrostatic communication was taken care of by particle mesh 
Ewald calculation while obliges bond lengths at their equilibrium cutoff 
were taken care of by SHAKE calculation [29,30]. Trajectories were 
accumulated in traj.trr document, and structural investigation was 
completed at each picoseconds. RMSD, root mean square fluctuation 
(RMSF), and hydrogen bonds analysis formed were examined with 
the help of Gromacs utilities, for example, utilities g_rms, g_rmsf, and 
g_hbond, respectively. In addition, the electrostatic properties for 
binding sites were also examined using Gromacs utility, g_potential.
RESULTS AND DISCUSSION
Binding residues analysis
The binding site residues of ROS1 were retrieved from the LCT program 
by employing the complex structure of ROS1-crizotinib (PDB ID: 3ZBF). 
The outcome designated a total of 10 amino acid residues, viz., L1951, 
A1978, L2026, E2027, L2028, M2029, G2032/R2032, D2083, R2083, 
and L2086 act as binding residues in the ROS1 structure.
Binding residues flexibility by means of NMA
Binding residue flexibility is a central way to figure out by which drug 
exerts biological effects. The binding flexibility allows elevated affinity 
to be achieved between a drug and its target enzyme. To understand 
the explanation of drug insensitivity by G2032 mutation, we used the 
program ElNemo to analyze and compare the flexibility of amino acids 
of both wild and mutants, which are involved in binding with crizotinib. 
Table 1 depicts the flexibility of amino acids in the drug-binding 
pocket of both wild and mutants by means of normalized mean square 
displacement (R2). We classified out this evidence into three different 
Table 1: Evaluation of normalized mean square displacement of 









displacement (R2) in 
mutant‑type (nm2)
1 L1951 0.0406 0.0370
2 A1978 0.0123 0.0164
3 L2026 0.0034 0.0052
4 E2027 0.0059 0.0059*
5 L2028 0.0070 0.0082
6 M2029 0.0171 0.0076
7 G2032 0.0198 0.0113
8 D2033 0.0177 0.0102
9 R2083 0.0115 0.0107
10 L2086 0.0084 0.0082
Bold indicates increased flexibility; italics indicates decreased flexibility, 
*Indicates identical flexibility
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ranges of flexibility. One is the R2 of amino acids in the drug-binding 
pocket of mutants which is absolutely the same as R2 of the amino acids in 
the drug-binding pocket of wild named as identical flexibility. The second 
was the R2 of amino acids in the drug-binding pocket of mutants which 
is above than R2 of the amino acids in the drug-binding pocket of wild 
named increased flexibility. And the last is the R2 of amino acids in the 
drug-binding pocket of mutants which is lesser than R2 of amino acids in 
the drug-binding pocket of wild named as decreased flexibility. From the 
above analysis, we figure out that out of ten preferred drug-binding sites, 
six of the binding amino acids were in the range of decreased flexibility 
and three of the binding amino acids were in the range of increased 
flexibility. On the other hand, only one of the binding amino acids was in 
the range of identical flexibility. This displays that more number of amino 
acids engaged in the drug-binding pocket of these mutants lost their 
flexibility due to their occurrence in the range of decreased flexibility. 
Flexibility of amino acids in drug-binding pocket, in fact, is thought to 
be a critical parameter to comprehend the binding efficiency. The loss 
of flexibility hinders the binding effect and the other way around [31]. 
These confirmations together with R2 data firmly imply that flexibility is 
critical for the binding of crizotinib with target structure.
Docking studies
The binding free energies of the wild and mutant types of ROS1-crizotinib 
complex resolution by ArgusLab 4.0.1 were −8.78 and −7.73 kcal/mol, 
respectively. To figure out the authentic analysis of binding affinity, the 
new trend in the field is the multiple docking algorithms. Finally, the 
results of the different algorithms were joined to balance the faults in 
the in-silico prediction. This approach is helpful in the ligand-binding 
inquiry for improving the anticipation of identifying true ligands. To 
justify this, binding affinity was also determined using the PEARLS 
program. The results are shown in Table 2.
The PEARLS program results showed that binding energies were 
found to be −8.80 and −6.60 kcal/mol for the wild- and mutant-
type structures of ROS1-crizotinib complex, respectively. Further, to 
strengthen the docking experiment, we have used AutoDock in our 
analysis [32,33]. The results showed that binding energies were found 
to be −7.68 and −6.08 kcal/mol for the wild- and mutant-type structures 
of ROS1-crizotinib complex, respectively. It indicates the average 
binding energy of wild ROS1-crizotinib complex as −8.42 kcal/mol and 
of mutant ROS1-crizotinib complex as −6.80 kcal/mol.
The experimental evidence also indicates that glycine at position 
2032 is conserved and arginine substitution at this highly conserved 
residue conferred resistance to ROS1 inhibitors. For instance, crizotinib 
concentration needed to achieve 50% enzyme inhibition (Ki) was 
increased by a factor of 270 for the G2032R mutant kinase as compared 
with non-mutant ROS1 [34]. Finally, the intermolecular hydrogen bonds 
in the complex structure were also shown using LIGPLOT to explain the 
mechanism of crizotinib resistance [35]. The results are shown in Fig. 1.
Hydrogen bonds are determined by dashed lines among the atoms 
involved, while hydrophobic contacts are shown by an arc with spokes 
radiating facing the ligand atoms they contact. The contacted atoms are 
delineated shown with spokes radiating back (Fig. 1).
It is clear from the figure that wild ROS1 structure can display two 
hydrogen bonds whereas mutant ROS1 structure can show only one 
hydrogen bond with crizotinib. N22 and N23 of crizotinib are convoluted 
in hydrogen bonding with E-2027 and M-2029, respectively, in the wild 
ROS1-crizotinib complex. On the other hand, in the mutant structure, 
N24 of crizotinib is involved in hydrogen bonding with M-2029. There 
is no hydrogen bond among E-2027 with crizotinib. To establish our 
prediction, we have also predicted the intermolecular distance utilizing 
PyMOL tool. The results indicates that distance between crizotinib and 
E2027 in wild-ROS1 is 3.56 Å whereas distance between crizotinib and 
E2027 in mutant-ROS1 is 10.38 Å (Fig. 2a and b).
Similarly, the distance between crizotinib and M2029 in mutant 
structure is also increased (Fig. 3a and b).
These alterations may have an effect on the protein function and 
binding free energy by generating changes in the interaction energy 
between crizotinib and ROS1 or affecting the conformations of these 
residues or local rigidity of the structure.
MD simulation
The MD simulations were executed for the wild and mutant G2032R 
crizotinib complex employing GROMACS package 4.5.3. RMSD, RMSF, 
hydrogen bond, and electrostatic potential details were evaluated. 
RMSD is the similarity between the two structures. It is evident 
Table 2: Binding free energy investigation of crizotinib with wild and mutant types of ROS1
S.No. Complex type Binding free energy by 
“ArgusLab” (kcal/mol)
Binding free energy by 
“PEARLS” (kcal/mol)
Binding free energy 
by “Autodock”
(kcal/mol)
Average binding free 
energy (kcal/mol)
1 Wild-type ROS1–crizotinib −8.78 −8.80 −7.68 −8.42
2 Mutant-type ROS1–crizotinib −7.73 −6.60 −6.08 −6.80
Fig. 1: The three-dimensional model of the active site and contact 
of crizotinib with (a) wild-type ROS1 (PDB Code 3ZBF) and 
(b) G2032R mutant type ROS1. Carbon, nitrogen, and oxygen 
atoms are shown as black, blue, and red balls; hydrogen‑bonded 
and non‑bonded protein‑ligand contacts are represented as 
dashed green lines and eyelashes, respectively
a
b
Fig. 2: Distances among crizotinib and E-2027 in (a) wild-type 
ROS1 and (b) mutant‑type ROS1
a b
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from the Figs. 4 and 5 that both the wild and mutant structures 
ROS1 have deviated. After the relaxation period, wild structure 
acquired ~0.32 nm at 1000 ps during the simulations, while mutant 
structure acquired ~0.25 nm of backbone RMSD at 1000 ps (Fig. 4a). 
Between a period of 2000 and 8000 ps, a wild structure is able to 
maintain ~0.30 nm of backbone RMSD, while a mutant structure 
showed frequent changes (~0.20 to ~0.28 nm) in backbone RMSD. Wild 
gained RMSD dominance over mutant and attained RMSD of ~0.35 nm 
at 10,000 ps. On the other hand, the mutant showed less deviation than 
the wild and achieved ~0.24 nm at 10,000 ps. At the end of 15,000 ps 
(Trail 1), the wild attained RMSD of ~0.30 nm whereas mutant 
structure attained RMSD of ~0.27 nm. In Trail 2, at the end of 15,000 
ps, the wild attained RMSD of ~0.33 nm whereas mutant structure 
attained RMSD of ~0.25 nm. The mutant structure deviated less from 
the starting structures, but the wild ROS1 showed more deviations. 
This magnitude of fluctuations together with the very small difference 
between the average RMSD values concluded that the simulations 
produced stable trajectories, thus providing a suitable basis for further 
analysis. Moreover, we have evaluated the flexibility behavior of the 
amino acid residues (Fig. 4b) in ROS1 by means of RMSF. Analysis 
of the fluctuations declared that the more degrees of flexibility were 
observed in the wild than in the mutant ROS1. Most importantly, there 
was an important variation in the flexibility observed, particularly in 
the region 1900-2300. The alteration in flexibility is further confirmed 
by the number of the intramolecular hydrogen bond (NH-bond) 
analysis (Fig. 4c). The analysis showed that mutant gained a slightly 
higher number of hydrogen bonds when compared to wild structure. 
During the 1000 ps, the wild structure showed an increase in H bonds 
compared to the mutant structure. It can be seen in Fig. 4c; the mutant 
structure generates 210 H bonds between periods of 3000 and 12,000 
ps whereas wild structure generates 202-209 H bonds between periods 
of 3000 and 12,000 ps. In Trail 1, at the end of 15,000 ps, the mutant 
structure generates 212 H bonds whereas wild structure generates 205 
H bonds.
In Trail 2, at the end of 15,000 ps, the mutant structure generates 209 H 
bonds whereas wild structure generates 201 H bonds. The frequency 
of the occurrence of the H-bond was slightly higher in the mutant 
structure than the wild structure. These variations within the H-bond 
networks in ROS1 structure affect the intrinsic flexibility of the protein. 
On the basis of NH-bond analysis, it is confirmed that the occurrence of 
the mutation leads to a loss of flexibility in the mutant ROS1 due to the 
formation of more hydrogen bonds. This enables that the wild structure 
exhibits stronger binding with crizotinib than the mutant structure.
It is believed that these hydrogen bonds are responsible for the integrity, 
maintenance, and slightly higher structural stability of the mutant 
structure than the wild structure. The simulation results also reveal 
the fact that the binding pocket of mutant enzyme has shown slightly 
rigid or non-flexible pocket than the binding pocket of wild-type. These 
behaviors enable the wild structure to exhibit a stronger binding with 
crizotinib than the mutant structure. Furthermore, to understand the 
electrostatic properties of wild and mutant structures, we analyzed 
the charge distribution of hydrophobic pocket residues throughout 
the simulation box in both wild and mutant structures. The Gromacs 
make_ndx command is used to select the binding pocket residues. The 
result is shown in Fig. 6.
It shows that there is an increase of charge in mutant binding pocket 
residues. The G2032R mutation introduces a charge at this position; 
this can cause repulsion between the mutated residue and neighboring 
residues. In addition, the introduction of a positive charge might 
Fig. 3: Distances among crizotinib and M-2029 in (a) wild-type 
ROS1 and (b) mutant‑type ROS1
a b
Fig. 4: (a) Root mean square deviation, (b) root mean square fluctuation and (c) NH bond of native and mutant type ROS1 complexes 
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influence the interactions with the partner molecule. Crizotinib is a 
targeted form of the drug that specially targets and kills lung cancer 
cells. Crizotinib resistance becomes a serious issue to lung cancer 
patients. Although previous findings suggested that drug resistance 
in ROS1is due to loop conformation changes, in our findings, we 
observed that intramolecular hydrogen bonds play an important in 
flexibility. Mutation leads to a loss of flexibility in the mutant ROS1 due 
to the formation of more intramolecular hydrogen bonds. Glutamic acid 
residue (E-2027) is absent in the mutant structure, and this residue is 
important for the effective binding and stability of the ROS1-crizotinib 
complex. Docking results indicated that mutant ROS1 structure 
significantly affected the binding affinity for crizotinib. We believe that 
this could be the important basis for the cause of drug insensitivity.
CONCLUSION
The advancement in structure prediction techniques and the 
development of computer simulation and MD have resulted in the 
increased prominence of rational drug design for finding new and 
improved drugs. The competence and effect of the rational drug design 
approach have minimized the drug development time. In this study, we 
have utilized the NMA and MD way to deal with addition knowledge into 
crizotinib-resistant G2032R mutation in the structure of ROS1. Detailed 
information about the molecular and structural properties of the wild 
and mutant types of ROS1 has been provided by this approach. Docking 
analysis clearly indicates that G2032R mutation significantly decreases 
the binding affinity for crizotinib than wild-type ROS1. In addition, the 
R2 and RMSF data obtained in the molecular simulation approach reveal 
that the fluctuation behavior of binding residues in the mutant structure 
is slightly different from the wild structure, and there was an increase 
in the number of intramolecular hydrogen bonds during MD simulation. 
This indicates that the G2032R mutation significantly stabilizes the 
structure of the mutant type ROS1. Our results indicate that glutamic 
acid residue (E-2027) is most probably needed to make enhanced 
interactions with crizotinib molecule. Finally, the charge distribution 
study clearly indicates the loss of hydrophobicity in the binding site due 
to G2032R mutation. Ideally, the work gives new experiences into the 
mechanism of drug resistance pattern in lung cancer and put forward a 
productive idea of devising NSCLC inhibitors.
ACKNOWLEDGMENTS
Dr. Anish Kumar expresses a deep sense of gratitude to Mr. Rajesh 
Kumar and Mrs. Neera Rani for constant encouragement provided by 
them through the research work.
REFERENCES
1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer 
J Clin 2012;62(1):10-29.
2. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. 
The protein kinase complement of the human genome. Science 
2002;298(5600):1912-34.
3. Kumar A, Shanthi V, Ramanathan K. Discovery of potential ALK 
inhibitors by virtual screening approach. 3 Biotech 2016;6:1-12.
4. Christensen JG, Zou HY, Arango ME, Li Q, Lee JH, McDonnell SR, 
et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor 
of anaplastic lymphoma kinase and c-Met, in experimental models of 
anaplastic large-cell lymphoma. Mol Cancer Ther 2007;6:3314-22.
5. Roberts PJ. Clinical use of crizotinib for the treatment of non-small cell 
Fig. 6: Charge density analysis of ROS1 along the molecular 
dynamics simulation. The symbol coding scheme is as follows: 
Wild (black) and mutant (red)
Fig. 5: (a) Root mean square deviation, (b) root mean square fluctuation and (c) NH bond of native and mutant type ROS1 complexes 




Asian J Pharm Clin Res, Vol 10, Issue 5, 2017, 339-344
 Kumar et al. 
lung cancer. Biologics 2013;7:91-101.
6. Cui JJ, Tran-Dubé M, Shen H, Nambu M, Kung PP, Pairish M, et al. 
Structure based drug design of crizotinib (PF-02341066), a potent and 
selective dual inhibitor of mesenchymal-epithelial transition factor 
(c-MET) kinase and anaplastic lymphoma kinase (ALK). J Med Chem 
2011;54(18):6342-63.
7. Shaw AT, Camidge DR, Engelman JA. Clinical activity of crizotinib 
inadvanced non-small cell lung cancer (NSCLC) harboring ROS1 gene 
rearrangement. J Clin Oncol 2012;30:7508.
8. Ou SH, Tan J, Yen Y, Soo RA. ROS1 as a ‘druggable’ receptor tyrosine 
kinase: Lessons learned from inhibiting the ALK pathway. Expert Rev 
Anticancer Ther 2012;12(4):447-56.
9. Kumar A, Shanthi V, Ramanathan K. Computational investigation 
and experimental validation of crizotinib resistance conferred by 
C1156Y mutant anaplastic lymphoma kinase. Mol Inform 2015;34(2-
3):105-14.
10. Kumar A, Ramanathan K. Analyzing resistance pattern of non-small 
cell lung cancer to crizotinib using molecular dynamic approaches. 
Indian J Biochem Biophys 2015;52(1):23-8.
11. Sun H, Li Y, Tian S, Wang J, Hou T. P-loop conformation governed 
crizotinib resistance in G2032R-mutated ROS1 tyrosine kinase: Clues 
from free energy landscape. PLoS Comput Biol 2014;10(7):e1003729.
12. Deng Y, Roux B. Computations of standard binding free energies with 
molecular dynamics simulations. J Phys Chem B 2009;113(8):2234-46.
13. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, 
et al. The protein data bank. Nucleic Acids Res 2000;28(1):235-42.
14. Guex N, Peitsch MC. SWISS-MODEL and the Swiss-PdbViewer: 
An environment for comparative protein modeling. Electrophoresis 
1997;18(15):2714-23.
15. Feldman HJ, Snyder KA, Ticoll A, Pintilie G, Hogue CW. A complete 
small molecule dataset from the protein data bank. FEBS Lett 
2006;580(6):1649-53.
16. López G, Valencia A, Tress ML. Firestar-prediction of functionally 
important residues using structural templates and alignment reliability. 
Nucleic Acids Res 2007;35:W573-7.
17. Yuan Z, Bailey TL, Teasdale RD. Prediction of protein B-factor profiles. 
Proteins 2005;58(4):905-12.
18. Parthasarathy S, Murthy MR. Protein thermal stability: Insights 
from atomic displacement parameters (B values). Protein Eng 
2000;13(1):9-13.
19. Hinkle A, Tobacman LS. Folding and function of the troponin tail 
domain. Effects of cardiomyopathic troponin T mutations. J Biol Chem 
2003;278(1):506-13.
20. Suhre K, Sanejouand YH. ElNemo: A normal mode web server 
for protein movement analysis and the generation of templates for 
molecular replacement. Nucleic Acids Res 2004;32:W610-4.
21. Langer T, Krovat EM. Chemical feature-based pharmacophores and 
virtual library screening for discovery of new leads. Curr Opin Drug 
Discov Devel 2003;6(3):370-6.
22. Wilson RP, Yusuf S. In silico design, docking, synthesis and 
antimicrobial evaluation of 2,5-disubstituted 1,3,4-oxadiazole 
derivatives. Int J Pharm Sci Res 2016;7(5):2074-82.
23. Oda A, Okayasu M, Kamiyama Y, Yoshida T, Takahashi O, Matsuzaki H. 
Evaluation of docking accuracy and investigation of roles of parameters 
and each term in scoring functions for protein-ligand docking using 
ArgusLab software. Bull Chem Soc Jpn 2007;80(10):1920-25.
24. Kumar A, Ramanathan K. Exploring the structural and functional 
impact of the ALK F1174L mutation using bioinformatics approach. 
J Mol Model 2014;20(7):2324.
25. Han LY, Lin HH, Li ZR, Zheng CJ, Cao ZW, Xie B, et al. PEARLS: 
Program for energetic analysis of receptor-ligand system. J Chem Inf 
Model 2006;46(1):445-50.
26. Chaitanya M, Babajan B, Anuradha CM, Naveen M, Rajasekhar C, 
Madhusudana P, et al. Exploring the molecular basis for selective 
binding of Mycobacterium tuberculosis Asp kinase toward its natural 
substrates and feedback inhibitors: A docking and molecular dynamics 
study. J Mol Model 2010;16(8):1357-67.
27. Hess B, Kutzner C, Spoel D, Lindahl E. GROMACS 4: Algorithms 
for highly efficient, load-balanced, and scalable molecular simulation. 
J Chem Theory Comput 2008;4(3):435-47.
28. Meagher KL, Carlson HA. Solvation influences flap collapse in HIV-1 
protease. Proteins 2005;58(1):119-25.
29. Darden T, Perera L, Li L, Pedersen L. New tricks for modelers from the 
crystallography toolkit: The particle mesh Ewald algorithm and its use 
in nucleic acid simulations. Structure 1999;7(3):R55-60.
30. van Gunsteren WF, Berendsen HJ. Algorithms for macromolecular 
dynamics and constraint dynamics. Mol Phys 1977;34(5):1311-27.
31. Rajasekaran R, George Priya Doss C, Sudandiradoss C, Ramanathan K, 
Purohit R, Sethumadhavan R. Effect of deleterious nsSNP on the 
HER2 receptor based on stability and binding affinity with herceptin: 
A computational approach. C R Biol 2008;331(6):409-17.
32. Chandran D, Pappachen LK, Prathap M, Jinsha MJ, Jilsha G. In silico 
drug design and molecular docking studies of some novel benzothiazole 
derivatives as anti-cancer and anti-inflammatory agents. Int J Pharm 
Pharm Sci 2014;6 Suppl:203-8.
33. Nishtha P, Kant PR, Raj ZN. Comparison of commercially available 
drugs for type 2 diabetes with natural molecule from tinospora. IJPPS 
2014;8(7):173-5.
34. Awad MM, Katayama R, McTigue M, Liu W, Deng YL, Brooun A, 
et al. Acquired resistance to crizotinib from a mutation in CD74-ROS1. 
N Engl J Med 2013;368(25):2395-401.
35. Wallace AC, Laskowski RA, Thornton JM. LIGPLOT: A program to 
generate schematic diagrams of protein-ligand interactions. Protein Eng 
1995;8(2):127-34.
